–{•¶‚ÖƒXƒLƒbƒv

‹ÆÑACHIEVEMENTS

˜_•¶

2024

  • Yamasaki K, Tokuno M, Tsukigawa K, Nagatsuka Y, Nishi K, Otagiri M, Sato Y, Possible involvement of protein binding inhibition in changes in dexmedetomidine concentration in extracorporeal circuits during midazolam use. Biol Pharm Bull. 2024;47(2):389-393. doi: 10.1248/bpb.b23-00659.
  • Commey KL, Enaka A, Nakamura R, Yamamoto S, Tsukigawa S, Nishi K, Iohara D, Hirayama F, Otagiri M, Yamasaki K, Development of ƒ¿-Cyclodextrin-Based Orally Disintegrating Tablets for 4-Phenylbutyrate. Pharmaceutics, 2024; 16,82. doi: 10.3390/pharmaceutics16010082.
  • Hasegawa T, Tsukigawa K, Commey K, Sakuragi M, Imoto S, Taguchi K, Nishi K, Otagiri M, Yamasaki K, Preparation and in vitro characterization of fatty-acid modified pirarubicin nanosuspensions stabilized by albumin. Chem Pharm Bull, 2024;72(1):21-27. doi: 10.1248/cpb.c23-00701.

2023

  • Commey K, Nakatake A, Enaka A, Nakamura R, Nishi K, Tsukigawa K, Ikeda H, Yamaguchi K, Iohara D, Hirayama F, Yamasaki K, Otagiri M, Study of the Structural Chemistry of the Inclusion Complexation of 4-Phenylbutyrate and Related Compounds with Cyclodextrins in Solution: Differences in Inclusion Mode with Cavity Size Dependency. Int J Mol Sci, 2023, 24(20), 15091. doi: 10.3390/ijms242015091
  • Yasuda K, Maeda H, Kinoshita R, Minayoshi Y, Mizuta Y, Nakamura Y, Imoto S, Nishi K, Yamasaki K, Sakuragi M, Nakamura T, Ikeda-Imafuku M, Iwao Y, Ishima Y, Ishida T, Iwakiri Y, Otagiri M, Watanabe H, Maruyama T, Encapsulation of an Antioxidant in Redox-Sensitive Self-Assembled Albumin Nanoparticles for the Treatment of Hepatitis. ACS Nano. 2023 Aug 14. doi: 10.1021/acsnano.3c02877.
  • ŸNŠÔŒ[ŠîAˆäŒû—L‹IA‚‘º˜aOA¼Œ´’ˆê˜NAŽRèŒ[”VAb”ã–L, ƒƒgƒƒjƒ_ƒ][ƒ‹—U”­«”]ÇŠ³ŽÒ‚Ì1—á |ŒŒ´’†ƒƒgƒƒjƒ_ƒ][ƒ‹‚¨‚æ‚уqƒhƒƒLƒVƒƒgƒƒjƒ_ƒ][ƒ‹”Z“x|. ’†“ÅŒ¤‹†, 2023; 36: 38-43.
  • Nishi K, Elucidation of Drug Transport Mechanism by Serum Protein and Development for Pancreatic Cancer Treatment. Yakugaku Zasshi. 2023;143(3):205-210. doi: 10.1248/yakushi.22-00173.
  • Yamasaki K, Teshima H,Yukizawa R; Kuyama K, Tsukigawa K, Nishi K, Otagiri M, Kawai A, Structural basis of the change in the interaction between mycophenolic acid and subdomain IIA of human serum albumin during renal failure. J Med Chem. 2023 Jan 12;66(1):951-961. doi: 10.1021/acs.jmedchem.2c01790. Epub 2022 Dec 20
  • Commey K, Nakatake A, Enaka A, Nishi K, Tsukigawa K, Yamaguchi K, Ikeda H, Iohara D, Hirayama F, Otagiri M, Yamasaki K, Study of the Inclusion Complexes Formed Between 4-Phenylbutyrate and ƒ¿-, ƒÀ-, and ƒÁ-Cyclodextrin in Solution and Evaluation on Their Taste-Masking Properties. J Pharm Pharmacol. 2023 Feb 8;75(2):236-244. doi: 10.1093/jpp/rgac090

2022

  • Kawai A, Kobashigawa Y, Hirata K, Morioka H, Imoto S, Nishi K, Chuang VTG, Yamasaki K, Otagiri M, The Chlorine Atoms of Aripiprazole Molecule Control the Geometry and Motion of Aripiprazole and Deschloro-aripiprazole in the Subdomain IIIA of Human Serum Albumin. ACS Omega. 2022 Aug 18;7(34):29944-29951. doi: 10.1021/acsomega.2c02929
  • Beppu T, Nishi K, Imoto S, Araki W, Setoguchi I, Ueda A, Suetsugi N, Ishima Y, Ikeda T, Otagiri M, Yamasaki K., Novel nitric oxide donor, nitrated phenylbutyrate, induces cell death of human pancreatic cancer cells and suppress tumor growth of cancer xenografts. Oncol Rep. 2022 Oct;48(4):178. doi: 10.3892/or.2022.8393
  • Ito C, Taguchi K, Moroi Y, Enoki Y, Tokuda R, Yamasaki K, Imoto S, Matsumoto K, Trimethoxy trityl groups as a potent substituent for anti-cancer cytidine analog prodrugs. J Pharm Sci. 2022, doi: 10.1016/j.xphs.2022.04.020.
  • Nishi K, Yano A, Tsukigawa K, Chuang VTG, Otagiri M, Yamasaki K., Effect of Fatty Acids and Uremic Toxins on the binding of Nateglinide, an Insulin Secretagogue, to Site II on Human Serum Albumin. Biol Pharm Bull. 2022;45(6):803-805. doi: 10.1248/bpb.b22-00116..
  • Nishi K, Imoto S, Beppu T, Uchibori S, Yano A, Ishima Y, Ikeda T, Tsukigawa K, Otagiri M, Yamasaki K., The Nitrated Form of Nateglinide Induces Apoptosis in Human Pancreatic Cancer Cells Through a Caspase-dependent Mechanism. Anticancer Res. 2022 Mar;42(3):1333-1338. doi: 10.21873/anticanres.15601.
  • Hirata K, Kawai A,, Chuang VTG, Sakurama K, Nishi K, Yamasaki K, Otagiri M, Effects of Myristate on the Induced Circular Dichroism Spectra of Aripiprazole Bound to Human Serum Albumin: A structural-chemical investigation.ACS Omega. 2022 Jan 27;7(5):4413-4419. doi: 10.1021/acsomega.1c06220.
  • Yamasaki K, Sakurama K, Nishi K, Tsukigawa K, Seo H, Otagiri M, Taguchi K, An in vitro comparative study of the binding of caspofungin and micafungin to plasma proteins. J Pharm Pharmacol. 2022 Jan 5;74(1):88-93. doi: 10.1093/jpp/rgab157.
  • Yamasaki K, Fujisaki-Hirakawa M, Taguchi K, Kadowaki D, Tsukigawa K, Nishi K, Otagiri M, Seo H, In vitro and in vivo assessment of Atemoya fruit (Annona atemoya) for food-drug interactions. Eur J Drug Metab Pharmacokinet. 2022 Mar;47(2):177-185. doi: 10.1007/s13318-021-00739-4.

2021

  • Hirata K, Ikeda T, Watanabe H, Maruyama T, Tanaka M, Chuang VTG, Uchida Y, Sakurama K, Nishi K, Yamasaki K, Otagiri M, The binding of aripiprazole to plasma proteins in chronic renal failure patients. toxins; 2021; 13: 811: https://doi.org/10.3390/toxins13110811
  • Nishi K, Sakurama K, Watanabe H, Maruyama T, Yamasaki K, Otagiri M, Effects of Uremic Toxins on the Binding of Aripiprazole to Human Serum Albumin. Biol Pharm Bull. 2021;44(3):437-441. doi: 10.1248/bpb.b20-00929.
  • Yamasaki K, Nishi K, Tsukigawa K, Taguchi K, Otagiri M, Seo H, Possible role of electrolytes on the formation of precipitates during the infusion of nafamostat mesilate in hemodialysis. Biol Pharm Bull. 2021; 44 (2): 259-265, doi.org/10.1248/bpb.b20-00808
  • Yamasaki K, Kawai A, Sakurama K, Udo N, Yoshino Y, Saito Y, Tsukigawa K, Nishi K, Otagiri M. Interaction of benzbromarone with subdomains IIIA and IB/IIA on human serum albumin as the primary and secondary binding regions. Mol Pharm. 2021 Mar 1;18(3):1061-1070. doi: 10.1021/acs.molpharmaceut.0c01004.
  • Yamada M, Tanahashi M, Yamasaki K, Taguchi K, Hirayama F, Seo H, Morioka J. Evaluation of Storage Stability of Acetic Acid Ointments as Hospital Preparations. (in Japanese), Jpn J Pharm Health Care Sci. 2021; 47 (3): 171-177
  • Yamasaki K, Hidaka M, Kawano Y, Furuya Y, Ono H, Arimori K, Possible roles of intestinal P-glycoprotein and cytochrome P450 3A on the limited oral absorption of irinotecan. J Pharm Pharmacol. 2021; 73 (2): 178-184. doi.org/10.1093/jpp/rgaa009
  • Ikeda-Ogata I, Yamasak Ki, Yokomizo K, Ikeda T, Seo H, Antipruritic and anti-herpes virus activities of bisabolol oxide A, the main constituent in the essential oil of German chamomile (Matricaria recutita L.). Cur Top Phytochem. 2021; 17: 63-68.
  • Hashimoto M, Taguchi K, Imoto S, Yamasaki K, Mitsuya H, Otagiri M, Pharmacokinetics of 4'-cyano-2'-deoxyguanosine, a novel nucleoside analog inhibitor of the resistant hepatitis B virus, in a rat model of chronic kidney disease. J Infect Chemother. 2021 May;27(5):702-706.

2020

  • Tsukigawa K, Imoto S, Yamasaki K, Nishi K, Tsutsumi T, Yokoyama S, Ishima Y, Otagiri M, Synthesis and In Vitro Assessment of pH-Sensitive Human Serum Albumin Conjugates of Pirarubicin. Pharmaceuticals (Basel). 2020 Dec 30;14(1):22. doi: 10.3390/ph14010022.
  • Hashimoto M, Taguchi K, Imoto S, Yamasaki K, Mitsuya H, Otagiri M, Pharmacokinetic Properties of Orally Administered 4'-Cyano-2'-deoxyguanosine, a Novel Nucleoside Analog Inhibitor of the Hepatitis B Virus, in Viral Liver Injury Model Rats. Biol Pharm Bull. 2020;43(9):1426-1429. doi: 10.1248/bpb.b20-00372.
  • Tokuno M, Taguchi K, Yamasaki K, Otagiri M , Hepatic cytochrome P450 profiles in hemorrhagic shock model rats after transfusion with stored red blood cells. J Pharm Sci. 2020 Nov;109(11):3490-3495. doi: 10.1016/j.xphs.2020.08.015.
  • Taguchi K, Chuang VTG, Hashimoto M, Nakayama M, Sakuragi M, Enoki Y, Nishi K, Matsumoto K, Seo H, Otagiri M, Yamasaki K, Characterization of Bovine Lactoferrin Nanoparticle Prepared by Desolvation Technique. Chem Pharm Bull (Tokyo). 2020;68(8):766-772. doi: 10.1248/cpb.c20-00222.
  • Tokuno M, Taguchi K, Sakai H, Ohtsuki S, Yamasaki K, Otagiri M, Assessing cytochrome P450-based drug-drug interactions with Hemoglobin-vesicles, an artificial red blood cell preparation, in healthy rats. Drug Metab Pharmacokinet. 2020 Oct;35(5):425-431. doi: 10.1016/j.dmpk.2020.06.005.
  • Tokuno M, Taguchi K, Sakai H, Ohtsuki S, Yamasaki K, Otagiri M, Evaluation of cytochrome P450-based drug metabolism in hemorrhagic shock rats that were transfused with native and an artificial red blood cell preparation, Hemoglobin-vesicles. Drug Metab Pharmacokinet. 2020 Oct;35(5):417-424. doi: 10.1016/j.dmpk.2020.06.004.
  • Yamasaki K, Sakurama K, Nishi K, Watanabe H, Maruyama T, Seo H, Otagir Mi, Taguchi K, Characterization of the interaction of daptomycin with site II on human serum albumin. J Pharm Sci. 2020 Sep;109(9):2919-2924. doi: 10.1016/j.xphs.2020.06.011.
  • Sakurama K, Nishi K, Chuang VTG, Hashimoto M, Yamasaki K, Otagiri M, Effects of Oxidation of Human Serum Albumin on the Binding of Aripiprazole. Biol Pharm Bull. 2020;43(6):1023-1026. doi: 10.1248/bpb.b20-00205.
  • Fukunaga M, Kadowaki D, Mori M, Hagiwara S, Narita Y, Saruwatari J, Tanaka R, Watanabe H, Yamasaki K, Taguchi K, Ito H, Maruyama T, Otagiri M, Hirata S., In vivo evaluation of drug dialyzability in a rat model of hemodialysis. PLoS One. 2020 Jun 12;15(6):e0233925. doi: 10.1371/journal.pone.0233925. eCollection 2020.
  • Nishi K, Yamasaki K, Otagiri M. Serum Albumin, Lipid and Drug Binding. Subcell Biochem. 2020. 94:383-397. doi: 10.1007/978-3-030-41769-7_15.
  • Hashimoto M , Chuang VTG, Ishima Y, Ikeda M, Maruyama T, Yamasaki K, Taguchi K, Otagiri M. A Safety Evaluation Study in Mice Revealed that Albumin Dimer is Safe for Medical and Pharmaceutical Applications, BPB Reports. 2020. 3: 87-91.
  • Yamasaki K, Iohara D, Oyama Y, Nishizaki N, Kawazu S, Nishi K, Kadowaki D, Taguchi K, Otagiri M, Seo H. Processing grapefruit juice with ƒÁ-cyclodextrin attenuates its inhibitory effect on cytochrome P450 3A activity. J Pharm Pharmacol. 2020 Mar;72(3):356-363. doi: 10.1111/jphp.13212. Epub 2019 Dec 11.

2019

  • Okamoto Y, Taguchi K, Imoto S, Giam Chuang VT, Yamasaki K, Otagiri M. Cell uptake and anti-tumor effect of liposomes containing encapsulated paclitaxel-bound albumin against breast cancer cells in 2D and 3D cultured models. J Drug Deliv Sci Tech. 2019. doi.org/10.1016/j.jddst.2019.101381
  • Nishi K, Sakurama K, Kobashigawa Y, Morioka H, Udo N, Hashimoto M, Imoto S, Yamasaki K, Otagiri M. Interaction of Aripiprazole with Human ƒ¿1-Acid Glycoprotein. J Pharm Sci. 2019 Sep 11. pii: S0022-3549(19)30568-4. doi: 10.1016/j.xphs.
  • Yamasaki K, Taguchi K, Nishi K, Otagiri M, Seo H. Enhanced dissolution and oral bioavailability of praziquantel by emulsification with human serum albumin followed by spray drying. Eur J Pharm Sci. 2019 Nov 1;139:105064. doi: 10.1016/j.ejps.2019.105064.
  • Matsusaka K, Ishima Y, Hitoshi M, Kinoshita R, Ichimizu S, Taguchi K, Giam Chuang VT, Nishi K, Yamasaki K, Otagiri M, Watanabe H, Maruyama T. ƒ¿1-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anti-Cancer Agents. J Pharm Sci. 2019 Jul 6. pii: S0022-3549(19)30434-4. doi: 10.1016/j.xphs.2019.07.002.
  • Okamoto Y, Taguchi K, Sakuragi M, Imoto S, Yamasaki K,Otagiri M. Preparation, Characterization, and in Vitro/in Vivo Evaluation of Paclitaxel-Bound Albumin-Encapsulated Liposomes for the Treatment of Pancreatic Cancer. ACS Omega, 2019 May, 4, 8693-8700. dio: 10.1021/acsomega.9b00537
  • Kimura K, Yamasaki K, Nishi K, Taguchi K, Otagiri M. Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation technique. Cancer Chemother Pharmacol. 2019 Jun;83(6):1113-1120. doi: 10.1007/s00280-019-03832-3.

2018

  • Sakurama K, Nishi K, Imoto S, Hashimoto M, Komatsu T, Morita Y, Taguchi K, Otagiri M, Yamasaki K. Further Evidence Regarding the Important Role of Chlorine Atoms of Aripiprazole on Binding to the Site II Area of Human Albumin. J Pharm Sci. 2018 Dec 8. pii: S0022-3549(18)30795-0. doi: 10.1016/j.xphs.2018.11.045
  • Nishi K, Suzuki M, Yamamoto N, Matsumoto A, Iwase Y, Yamasaki K, Otagiri M, Yumita N. Glutamine Deprivation Enhances Acetyl-CoA Carboxylase Inhibitor-induced Death of Human Pancreatic Cancer Cells. Anticancer Res. 2018 Dec;38(12):6683-6689. doi: 10.21873/anticanres.13036.
  • Sakurama K, Kawai A, Tuan Giam Chuang V, Kanamori Y, Osa M, Taguchi K, Seo H, Maruyama T, Imoto S, Yamasaki K, Otagiri M. Analysis of the Binding of Aripiprazole to Human Serum Albumin: The Importance of a Chloro-Group in the Chemical Structure. ACS Omega. 2018 Oct 31;3(10):13790-13797. doi:10.1021/acsomega.8b02057.
  • Hashimoto M, Taguchi K, Ishiguro T, Kohgo S, Imoto S, Yamasaki K, Mitsuya H, Otagiri M. Pharmacokinetic properties of a novel inosine analog, 4'-cyano-2'-deoxyinosine, after oral administration in rats. PLoS One. 2018 Jun 6;13(6):e0198636. doi: 10.1371/journal.pone.0198636. eCollection 2018.
  • Yamasaki K, Nishi K, Anraku M, Taguchi K, Maruyama T, Otagiri M. Metal-catalyzed oxidation of human serum albumin does not alter the interactive binding to the two principal drug binding sites. Biochem Biophys Rep. 2018 May 11;14:155-160. doi: 10.1016/j.bbrep.2018.05.002. eCollection 2018 Jul.
  • Taguchi K, Nagao S, Maeda H, Yanagisawa H, Sakai H, Yamasaki K, Wakayama T, Watanabe H, Otagiri M, Maruyama T. Biomimetic carbon monoxide delivery based on hemoglobin vesicles ameliorates acute pancreatitis in mice via the regulation of macrophage and neutrophil activity. Drug Deliv. 2018 Nov;25(1):1266-1274. doi:10.1080/10717544.2018.1477860.
  • Taguchi K, Maruyama T, Otagiri M. Use of hemoglobin for delivering exogenous carbon monoxide in medicinal applications. Curr Med Chem. 2018 Nov 13. doi: 10.2174/0929867325666181113122340.
  • Kimura K, Yamasaki K, Nakamura H, Haratake M, Taguchi K, Otagiri M. Preparation and in Vitro Analysis of Human Serum Albumin Nanoparticles Loaded with Anthracycline Derivatives. Chem Pharm Bull (Tokyo). 2018;66(4):382-390. doi:10.1248/cpb.c17-00838.
  • Okamoto Y, Taguchi K, Sakuragi M, Imoto S, Yamasaki K, Otagiri M. In vivo drug delivery efficiency of albumin-encapsulated liposomes as hydrophobic drug carriers.ournal of Drug Delivery Science and Technology. 2018; 47: 62-66. doi.org/10.1016/j.jddst.2018.07.001.
  • Hashimoto M, Taguchi K, Ishiguro T, Kohgo S, Imoto S, Yamasaki K, Mitsuya H, Otagiri M. Pharmacokinetics studies of 4'-cyano-2'-deoxyguanosine, a potent inhibitor of the hepatitis B virus, in rats. J Pharm Pharmacol. 2018 Jun;70(6):723-731. doi: 10.1111/jphp.12897.
  • Kawai A, Yamasaki K, Enokida T, Miyamoto S, Otagiri M. Crystal structure analysis of human serum albumin complexed with sodium 4-phenylbutyrate. Biochem Biophys Rep. 2018 Jan 28;13:78-82. doi: 10.1016/j.bbrep.2018.01.006.

2017

  • Matsushita S, Nishi K, Iwao Y, Ishima Y, Watanabe H, Taguchi K, Yamasaki K, Maruyama T, Otagiri M. Recombinant Human Serum Albumin Containing 3 Copies of Domain I, Has Significant in Vitro Antioxidative Capacity Compared to the Wild-Type. Biol Pharm Bull. 2017;40(10):1813-1817. doi: 10.1248/bpb.b17-00528.
  • Okamoto Y, Taguchi K, Yamasaki K, Sakuragi M, Kuroda S, Otagiri M. Albumin-Encapsulated Liposomes: A Novel Drug Delivery Carrier With Hydrophobic Drugs Encapsulated in the Inner Aqueous Core. J Pharm Sci. 2018 Jan;107(1):436-445. doi: 10.1016/j.xphs.2017.08.003.
  • Yamasaki K, Hyodo S, Taguchi K, Nishi K, Yamaotsu N, Hirono S, Chuang VTG, Seo H, Maruyama T, Otagiri M. Long chain fatty acids alter the interactive binding of ligands to the two principal drug binding sites of human serum albumin. PLoS One. 2017 Jun 29;12(6):e0180404. doi: 10.1371/journal.pone.0180404.
  • Kawai A, Chuang VTG, Kouno Y, Yamasaki K, Miyamoto S, Anraku M, Otagiri M. Crystallographic analysis of the ternary complex of octanoate and N-acetyl-l-methionine with human serum albumin reveals the mode of their stabilizing interactions. Biochim Biophys Acta Proteins Proteom. 2017 Aug;1865(8):979-984. doi: 10.1016/j.bbapap.2017.04.004. Epub 2017 May 1.
  • Yamasaki K, Enokida T, Taguchi K, Miyamura S, Kawai A, Miyamoto S, Maruyama T, Seo H, Otagiri M. Species Differences in the Binding of Sodium 4-Phenylbutyrate to Serum Albumin. J Pharm Sci. 2017 Sep;106(9):2860-2867. doi:10.1016/j.xphs.2017.04.025. Epub 2017 Apr 26.
  • Taguchi K, Yamasaki K, Sakai H, Maruyama T, Otagiri M. The Use of Hemoglobin Vesicles for Delivering Medicinal Gas for the Treatment of Intractable Disorders. J Pharm Sci. 2017 Sep;106(9):2392-2400. doi: 10.1016/j.xphs.2017.04.006. Epub 2017 Apr 13. Review.
  • Taguchi K, Yamasaki K, Maruyama T, Otagiri M. Comparison of the Pharmacokinetic Properties of Hemoglobin-Based Oxygen Carriers. J Funct Biomater. 2017 Mar 18;8(1). pii: E11. doi: 10.3390/jfb8010011. Review.
  • Yamasaki K, Sato H, Minagoshi S, Kyubun K, Anraku M, Miyamura S, Watanabe H, Taguchi K, Seo H, Maruyama T, Otagiri M. The Binding of Silibinin, the Main Constituent of Silymarin, to Site I on Human Serum Albumin. Biol Pharm Bull. 2017;40(3):310-317. doi: 10.1248/bpb.b16-00790.

2016

  • Tokuno M, Taguchi K, Yamasaki K, Sakai H, Otagiri M. Long-Term Stored Hemoglobin-Vesicles, a Cellular Type of Hemoglobin-Based Oxygen Carrier, Has Resuscitative Effects Comparable to That for Fresh Red Blood Cells in a Rat Model with Massive Hemorrhage without Post-Transfusion Lung Injury. PLoS One. 2016 Oct 31;11(10):e0165557. doi: 10.1371/journal.pone.0165557. eCollection 2016.
  • Enokida T, Yamasaki K, Okamoto Y, Taguchi K, Ishiguro T, Maruyama T, Seo H, Otagiri M. Tyrosine411 and Arginine410 of Human Serum Albumin Play an Important Role in the Binding of Sodium 4-Phenylbutyrate to Site II. J Pharm Sci. 2016 Jun;105(6):1987-1994. doi: 10.1016/j.xphs.2016.03.012. Epub 2016 Apr 22.
  • Kouno Y, Anraku M, Yamasaki K, Okayama Y, Iohara D, Nakamura H, Maruyama T, Hirayama F, Kragh-Hansen U, Otagiri M. N-acetyl-L-methionine is a superior protectant of human serum albumin against post-translational oxidation as compared to N-acetyl-L-tryptophan. Biochem Biophys Rep. 2016 Apr 26;6:266-274. doi: 10.1016/j.bbrep.2016.04.011. eCollection 2016 Jul.

ƒoEEi[ƒXƒy[ƒX

’é‘åŠw@–òŠw•”

§860-0082
ŒF–{Žs¼‹æ’r“c4-22-1

TEL 096-326-4163
FAX 096-326-5048